Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q2 2025
Amphastar Pharmaceuticals (AMPH) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Amphastar Pharmaceuticals (AMPH) reported revenue of $174M for the second quarter 2025 (Q2 2025), -4% from a year earlier and +2% from the quarter before. Operating margin was 24.2%, net earnings $31.0M (17.8% of revenue).
Amphastar Pharmaceuticals, Q2 2025: revenue $174M (-4% year over year), operating margin 24.2%, net earnings $31.0M, operating cash flow $35.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $174M | +2% | -4% |
| Gross profit | $86.5M | +1% | -9% |
| Operating profit | $42.2M | +13% | -24% |
| Net earnings | $31.0M | +23% | -18% |
| Operating cash flow | $35.6M | +1% | -48% |
| Free cash flow | $25.0M | +3% | -60% |
What changed
Revenue was $174.4M in Q2 2025, down 4% year over year and up 2% from the previous quarter.
Gross margin was 49.6%, down 2.6 points from a year earlier. Operating profit was $42.2M, a 24.2% margin (down 6.1 points year over year). Operating expenses grew 11% against a revenue fall of 4%. The fastest-growing cost line was Research & development (+14%). Net earnings were $31.0M, down 18% year over year. The effective tax rate was 21.1%.
Operating cash flow was $35.6M (down 48% year over year), 115% of net earnings. Non-cash charges added back $14.6M of depreciation and amortization and $6.4M of share-based compensation. Working capital and other items used $16.4M. Capital expenditures of $10.6M left free cash flow of $25.0M.
Questions
What was Amphastar Pharmaceuticals' revenue in the second quarter 2025?
Amphastar Pharmaceuticals (AMPH) reported revenue of $174M for the second quarter 2025 (Q2 2025), -4% from a year earlier and +2% from the quarter before.
Was Amphastar Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $42.2M (24.2% of revenue) and net earnings $31.0M.